Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor

References

• Isaksson E, von Schoultz E, Odlind V, etal. Effects of oral contraceptives on breast epithelial prolifera-tion. Breast Cancer Res Treat 2001;5:163–9
   Google Scholar
• Shapiro S, Rosenberg L, Hoffman M, etal. Risk of breast cancer in relation to the use of injectable p ro gesto gen contraceptives and combined estrogen/progestogen contraceptives. Am J Epi-demiol 2000;151:396–403
   PubMed Web of Science ®Google Scholar
• Skegg DC, Paul C, Spears GF, et al. Progestogen-only oral contraceptives and risk of breast cancer in New Zealand. Cancer Causes Control 1996;7: 513–19
   PubMedGoogle Scholar
• La Vecchia C, Altieri A, Franceschi S, etal. A. Oral contraceptives and cancer: update. Drug Saf 2001; 24:741–54
   PubMed Web of Science ®Google Scholar
• Jordan VC, Jeng MH, Catherino WH, et al. The estrogenic activity of synthetic progestins used in oral contraceptives. Cancer 1993;71:1501–5
   PubMed Web of Science ®Google Scholar
• Hofieth LJ, Raafat AM, Osuch JR, etal. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559–65
   PubMedGoogle Scholar
• Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen—progestins replacement therapy and breast cancer risk. J Am Med Assoc 2000;283:485–91
   PubMed Web of Science ®Google Scholar
• Ross RK, Paganini-Hill A, Wan PC, etal. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestins. J Natl Cancer Inst 2000;92:324–32
   Google Scholar
• Kaulsay KK, Zhu T, Bennett W, etal. The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology 2001;142:767–77
   PubMedGoogle Scholar
• van Garderen E, Swennenhuis JF, Hellmen E, etal. Growth hormone induces tyrosyl phosphorylation of the transcription factors Stat5a and Stat5b in CMT-U335 canine mammary tumor cells. Domest Anim Endocrinol 2001;20:123–35
   PubMedGoogle Scholar
• Muller AF, Janssen JA, de Herder WW, et al. Growth hormone receptor antagonists: potential indications. Ned Tijdschr Geneesk 2001;145:69–73
   PubMedGoogle Scholar
• Dolan JT, Miltenburg DM, Granchi TS, et al. Treatment of metastatic breast cancer with so mato-statin analogues — a meta-analysis. Ann Surg Oncol 2001;8:227–33
   PubMedGoogle Scholar
• Helle SI, Geisler J, Anker GB, et al. Alterations in the insulin-like growth factor system during treat-ment with diethylstilboestrol in patients with meta-static breast cancer. Br J Cancer 2001;85:147–51
   PubMed Web of Science ®Google Scholar
• Mandala M, Moro C, Ferretti G, et al. Effect of tamoxifen on GH and IGF-1 serum level in stage I—II breast cancer patients. Anticancer Res 2001;21: 585–8
   PubMedGoogle Scholar
• Jernstrom H, Chu W, Vesprini D, et al. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab 2001;72:144–54
   PubMed Web of Science ®Google Scholar
• Adams TE, Epa VC, Garrett TP, etal. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000;57:1050–93
   PubMed Web of Science ®Google Scholar
• Thuneke I, Schulte HM, Bamberger AM. Biphasic effect of medroxyprogesterone-acetate (MPA) treatment on proliferation and cyclin D1 gene transcription in T47D breast cancer cells. Breast Cancer Res Treat 2000;63: 243–8
   Google Scholar
• So derqvist G. Effects of sex steroids on proliferationin normal mammary tissue. Ann Med 1998;30: 511–24
   Google Scholar
• Botella J, Duranti E, Duc I, et al. Inhibition by nomegestrol acetate and other synthetic progester-one proliferation and progesterone receptor con-tent of T47-D human breast cancer cells. J Steroid Biochem Mol Biol 1994;50:41–7
   PubMed Web of Science ®Google Scholar
• Lantinga-van Leeuwen IS, van Garderen E, et al. Cloning and cellular localization of the canine pro-gesterone receptor: co-localization with growth hormone in the mammary gland. J Steroid Biochem Mol Biol 2000;75:219–28
   Google Scholar
• Mol JA, Selman PJ, Sprang EP, et al. The role of progestins, insulin-like growth factor (IGF) and IGF-binding proteins in the normal and neoplastic mammary gland of the bitch: a review. J Reprod Fertil Suppl 1997;51:339–44
   PubMedGoogle Scholar
• Mol JA, van Garderen E, Rutteman GR, etal. New insights in the molecular mechanism o f progestins-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans. J Steroid Biochem Mol Biol 1996; 57:67–71
   PubMed Web of Science ®Google Scholar
• Lee NC, Rosero-Bixby L, Oberle MW, et al. A case—control study of breast cancer and hormonal contraception in Costa Rica. J Natl Cancer Inst 1987;9:1247–54
   Google Scholar
• Z era RT, Danielson D, Van Camp JM, etal. Atypi-cal hyperplasia, proliferative fibro cystic change, and exogenous hormone use. Surgery 2001;130:732–7
   PubMedGoogle Scholar
• Gregoraszczuk EL, Milewicz T, Kolodziejczyk J, et al. Progesterone-induced secretion of growth hormone, insulin-like growth factor-I and pro-lactin by human breast cancer explants. Gynecol Endocrinol 2001;15:251–8
   PubMed Web of Science ®Google Scholar
• Wilde MI, Balfour JA. Gestodene? A review of its pharmacology, efficacy and tolerability in com-bined contraceptive preparations. Drugs 1995;50: 364–95
   PubMed Web of Science ®Google Scholar
• Iqbal MJ, Colletta AA, Houmayoun-Valyani SD, Baum M. Differences in oestrogen receptors in malignant and normal breast tissue as identified by the binding of a new synthetic progesto gen. Br J Cancer 1986;54:447–52
   Google Scholar
• McCarty MF. Androgenic progestins amplify the breast cancer risk associated with hormone replace-ment therapy by boosting IGF-I activity. Med Hypotheses 2001;56:213–16
   PubMedGoogle Scholar
• Connor CE, Norris JD, Broadwater G, et al., Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res 2001;7:2917–22
   Google Scholar
• Shiue C, Shiue GG, Benard F, et al. N-(n-Benzylpiperidin-4-y1)-2-[18F]fluoro-benzamide: a potential ligand for PET imaging of breast cancer. Nud Med Biol 2000;8:763–7
   Google Scholar
• Croce MV, Colussi AG, Segal-Eiras A. Assessment of methods for primary tissue culture of human breast epithelia. J Exp Clin Cancer Res 1998; 17:19–26
   PubMed Web of Science ®Google Scholar
• Huff KK, Kaufman D, Gabbay KH, etal. Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res 1986; 46:4613–19
   PubMed Web of Science ®Google Scholar
• Karey KP, Sirbasku DA. Differential responsivness of human breast cancer cell lines MCF-7 and T47D to growth factors and 1713-estradiol. Cancer Res 1998;48:4083–92
   Google Scholar
• Santen RJ, Pinkerton J, McCartney C, etal. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86:16–23
   PubMed Web of Science ®Google Scholar
• Baserga R. Controlling IGF-receptor function: a possible strategy for tumor therapy. Trends Biotechnol 1996;14:150–2
   PubMedGoogle Scholar
• Yang XF, Beamer W, Huynh HT, et al. Reduced growth of human breast cancer xenografts in hosts homozygous for the 'lit' mutation. Cancer Res 1996;56:1509–11
   PubMed Web of Science ®Google Scholar
• Pollak M, Schally AV. Mechanism of antineoplastic action of somatostatin analogues. Proc Soc Exp Biol Med 1998;217:143–52
   PubMed Web of Science ®Google Scholar
• Weckbecker G, Tolcvai L, Stolz B, et al. Somato-statin analogue octerotide enhances the anti-neoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene induced rat mammary carcinomas. Can Res 1994;54:6334–7
   PubMed Web of Science ®Google Scholar
• Yee D, Palik S, Lebovic GS, et al. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989;3:509–17
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Kitten 14, Coronado EB, et al. Blockade of the type 1 somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989;84: 1418–23
   Google Scholar
• Jeng MH, Parker CJ, Jordan VC. Estrogenic poten-tial of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992;52:6539–42
   Google Scholar
• van der Burg B, Kalkhoven E, Isbrucker L, et al. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol 1992;42:457–65
   PubMed Web of Science ®Google Scholar
• Baldwin CJ, Peter AT, Bosu WT, etal. The contra-ceptive effects oflevonorgestrel in the domestic cat. Lab Anim Sci 1994;44:261–9
   PubMedGoogle Scholar
• Murphy LJ, Murphy LC, Stead B, etal. Modulation of lactogenic receptors by progestins in cultured human breast cancer cells. J Clin Endocrinol Metab 1986;62:280–7
   PubMedGoogle Scholar
• Selman PJ, Mol JA, Rutteman GR, et al. Progestins-induced growth hormone excess in the dog originates in the mammary gland. Endocrinology 1994;134:287–92
   PubMed Web of Science ®Google Scholar
• Peters MG, Vanzulli S, Elizalde PV, et al. Effects of antiprogestins RU486 and ZK98299 on the expression of cell cycle proteins of a medroxy-progesterone acetate (MPA)-induced murine mammary tumor. Oncol Rep 2001;8:445–9
   PubMedGoogle Scholar
• Elizalde PV, Lanari C, Molinolo AA, etal. Involve-ment of insulin-like growth factors-I and -II and their receptors in medroxyprogesterone acetate-induced growth of mouse mammary adenocarcinomas. J Steroid Biochem Mol Biol 1998; 67:305–17
   PubMed Web of Science ®Google Scholar
• Sakamoto S, Hara Y, Mitamura T, et al. Additive effects of medroxyprogesterone acetate and 5-fluorouracil derivative on 7,12- dimethylb enz [a] anthracene-induced rat mammary tumors. Anti-Cancer Drugs 1998;9:351–7
   PubMedGoogle Scholar
• Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen—progestin on mammo-graphic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investi-gators. Ann Intern Med 1999;130:262–9
   Google Scholar
• Wunderlich M. Mild—moderate and severe dysplasia in exfoliative cytological studies of breast secretions in connection with use of oral contra-ceptives. Zentralbl Gynakol 1994;116:622–7
   PubMedGoogle Scholar
• Nishino Y, Neumann F. Estrogenic partial effect of norethisterone enanthate in relation to tumor induction in rat mammary gland. Arch Toxicol Suppl 1979;2:439–43
   Google Scholar
• Graf KJ, Etreby MF. The role of the anterior pituitary gland in progesterone-induced prolifera-tive mammary gland changes in the beagle. Arzneimittel-Forschung 1978;28:54–8
   PubMedGoogle Scholar
• Desmond WJ Jr, Wolbers SJ, Sato G. Cloned mouse mammary cell lines requiring androgens for growth in culture. Cell 1976;8:79–86
   Google Scholar
• Baratta M, Grolli S, Poletti A, et al. Role of andro-gens in proliferation and differentiation of mouse mammary epithelial cell line HC11. J Endocrinol 2000;167:53–60
   PubMedGoogle Scholar
• Hackenberg R, Hofmann J, Holzel F, et al. Stimulatory effects of androgen and antiandrogen on the in vitro proliferation of human mammary carcinoma cells. J Cancer Res Clin Oncol 1988; 114:593–601
   PubMed Web of Science ®Google Scholar
• Magnusson C, Baron JA, Correia N, et al. Breast cancer risk following long-term oestrogen and oestrogen—progestin replacement therapy. Int J Cancer 1999;339–44
   PubMedGoogle Scholar
• Calzada L, Martinez JM, Sandoval T. Hormone-related factors associated with hormone receptor levels in breast cancer. Gynecol Obstet Invest 2001; 52:264–8
   Google Scholar